|
|
|
|
|
|
|
|
|
16.04.25 - 00:03
|
Theratechnologies Provides Update on Sale Process (GlobeNewswire EN)
|
|
|
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the “Special Committee”), to oversee the process and make a recommendation to the full Board. To support this process, in addition to Barclays as financial advisor and Fasken as legal advisor, the Special Committee has also engaged Raymond James as independent financial advisor and Norton Rose Fulbright as independent legal advisor....
|
|
|
|
|
|
|
|
|
11.04.25 - 16:00
|
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value (Business Wire)
|
|
|
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. (“Theratechnologies”) (NASDAQ: THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51 to $4.50 per share.
The proposal represents a total enterprise value of up to $255 million, comprising:
$205 million in cash at closing, and
Up to $50 million in contingent value right (CVR) payments, including:
50% of the annual EGRIFTA® franchise gross profit (defined as net sales minus cost of goods, per U.S. GAAP) above $30 million annually for three years post-closing.
A $10 million one-time milestone payment if cumulative EGRIFTA gross profit exceeds $125 million over the same three-year period.
This offer implies a 164% to 238% premium to Theratechnologies' closing stock price of $1.33 as of April ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.25 - 13:33
|
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 (GlobeNewswire EN)
|
|
|
MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2024, ended November 30, 2024. All figures are in U.S. dollars unless otherwise stated....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
